Strata Critical Medical, Inc. is dedicated to supporting healthcare providers throughout the United States by offering swift logistical management and specialized medical ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.01 · Revenue $72.67M · 2 analysts
Est. EPS $0.01 · Revenue $78.26M · 2 analysts
Est. EPS $-0.09 · Revenue $290.80M · 2 analysts
Est. EPS $0.02 · Revenue $80.50M · 1 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $197.1M | -20.7% | +7.6% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $41.3M | +251.4% | -588.2% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +20.9% | -11.9% | +0.2% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -11.3% | +16.9% | -69.0% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | +21.0% | +291.0% | -553.7% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-59.9M | -68.7% | +281.8% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -30.4% | -112.9% | +268.9% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 1.2% | -71.8% | -2.6% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 6.38x | -9.9% | -55.4% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $325.5M | +26.8% | +1.6% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | 0.50 vs -0.01 | +5100.0% | -0.12 vs -0.02 | -500.0% |
| Revenue Surprise | $197.1M vs $213.8M | -7.8% | $72.5M vs $67.6M | +7.2% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Aug 10, 2026 | Love Reginald | director | Class A common stock, $0.0001 par value per share | D | 5,091 | $5.75 |
| Jul 31, 2026 | Wunsch Scott M | officer: CEO, Logistics | Class A common stock, $0.0001 par value per share | D | 13,992 | $5.09 |
| Jul 31, 2026 | Heyburn William A. | director, officer: Co-CEO and CFO | Class A common stock, $0.0001 par value per share | D | 199,209 | $5.09 |
| Jul 31, 2026 | Tomkiel Melissa M. | director, officer: Co-CEO and General Counsel | Class A common stock, $0.0001 par value per share | D | 212,309 | $5.09 |
| Jul 31, 2026 | Cohen Amir | officer: Chief Accounting Officer | Class A common stock, $0.0001 par value per share | D | 34,015 | $5.09 |
Operator: Good morning, ladies and gentlemen, and welcome to the Strata Critical Medical Fiscal Second Quarter 2026 Earnings Release Conference Call. [Operator Instructions] As a reminder, this call is being recorded. I would now like to turn the conference over to Matt Schneider, CFO of Clinical Services and Vice President of Finance and Investor Relations. Matt, you may begin. Mathew Schneider: Thank you for standing by, and welcome to Strata's conference call and webcast for the quarter ended June 30, 2026. We appreciate everyone joining us today. Before we get started, I would like to remind you of the company's forward-looking statement and safe harbor language. Statements made in this conference call that are not historical facts, including statements about future time periods, may be deemed to constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties, and actual future results may differ materially from those expressed or implied by the forward-looking statements. We refer you to our SEC filings, including our annual report on Form 10-K and our quarterly report on Form 10-Q, each as filed with the SEC for a more detailed discussion of the risk factors that could cause these differences. Any forward-looking statements provided during this conference call are made only as of the date of this call. As stated in our SEC filings, Strata disclaims any intent or obligation to update or revise these forward-looking statements, except as required by law. During today's call, we will also discuss certain non-GAAP financial measures, which we believe may be useful in evaluating our financial performance. A reconciliation of the most directly historical comparable consolidated GAAP financial measures to those historical non-GAAP financial measures is provided in our earnings press release and investor presentation. Our press release, investor presentation and Form 10-Q and 10-K filings are available on the Investor Relations section of our website at ir.stratacritical.com. These non-GAAP measures should not be considered in isolation or a substitute for financial results prepared in accordance with GAAP. Hosting today's call are our co-CEOs, Will Heyburn and Melissa Tomkiel. I'll now turn the call over to Melissa. Melissa Tomkiel: Thank you, Matt, and good morning, everyone. We are pleased to report strong results for the second quarter of 2026, highlighted by accelerating growth in our clinical business, increased cash flow generation and great progress on our capital deployment plan. On an organic basis, excluding acquisitions made during Q2, clinical revenue increased 15.1% sequentially in Q2 2026, driven by 23.8% growth in Transplant Clinical revenue, while Clinical gross margins rose to 26.1% in Q2 2026, up from 25% in Q1. We generated $5.7 million of operating cash flow and $2.9 million of free cash flow in the …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Melissa Tomkiel | Co- CEO, General Counsel, Corporate Secretary & Director | USD 1,134,548 | Female | 1981 | Active |
William A. Heyburn | Co-CEO, CFO & Director | USD 1,101,200 | Male | 1989 | Active |
Scott Wunsch | Chief Executive Officer of Logistics Services | USD 829,594 | Male | 1977 | Active |
Amir Cohen | Chief Accounting & Integration Officer | USD 596,000 | Male | 1977 | Active |
Scott Silvestry | Chief Medical Officer | — | — | — | Active |
Keith Trepanier | Chief of Safety | — | Male | — | Active |
Louis Verdetto | Chief Executive Officer of Clinical Services | — | Male | 1984 | Active |
Mathew Schneider | CFO of Clinical Services & VP of Finance and Investor Relations | — | Male | — | Active |
Strata Critical Medical, Inc. (SRTA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
The mean of analysts' price targets for Strata Critical Medical, Inc. (SRTA) points to a 47.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Strata Critical Medical, Inc. (SRTA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
The consensus price target hints at a 60% upside potential for Strata Critical Medical, Inc. (SRTA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Strata Critical Medical, Inc. (SRTA) Q2 2026 Earnings Call Transcript
